Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 6/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.54 |
| ▸ | BLM | P54132 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclandelate SCHEMBL5123 | 1.00 | LMNA (1.00) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| Cyclandelate SCHEMBL8060819 | 1.00 | LMNA (1.00) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| Cyclandelate SCHEMBL9705893 | 0.86 | LMNA (0.74) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| Cyclandelate SCHEMBL9705887 | 0.84 | LMNA (0.70) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| Eucatropine SCHEMBL132347 | 0.79 | CYP2D6 (1.00) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| SCHEMBL13894203 | 0.78 | LMNA (0.71) | LMNANR1I2ABCB11CYP2C9CYP3A4 | |
| Eucatropine SCHEMBL636552 | 0.78 | LMNA (1.00) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| SCHEMBL6908933 | 0.77 | ALDH1A1 (0.84) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| SCHEMBL3846512 | 0.77 | ALDH1A1 (0.84) | LMNANR1I2ABCB11CYP2D6CYP2C9 | |
| SCHEMBL3846508 | 0.77 | ALDH1A1 (0.84) | LMNANR1I2ABCB11CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011083188-A1 | ROBOTISED DEVICE FOR INSPECTING PIPES | FUNDACION CARTIF (ES) | 2011-07-14 | — | — | WO | claimed |
| US-12595504-B2 | Methods for screening compounds for bactericidal activity and for determining the sensitivity of bacterial samples | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2026-04-07 | — | — | US | disclosed |
| US-12227795-B2 | Molecular programming tools | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-02-18 | — | — | US | disclosed |
| WO-2025012495-A1 | APPARATUS, SYSTEM AND METHOD FOR MONITORING THE AGING AND/OR MACERATION PROCESSES OF AN ALCOHOLIC BEVERAGE IN A BARREL AND ALCOHOLIC BEVERAGE OBTAINED | PRODUCTOS AGROVIN, S.A. (ES) | 2025-01-16 | — | — | WO | disclosed |
| US-20240417804-A1 | KIT, DEVICE AND METHOD FOR DISTINGUISHING BETWEEN OVARIAN CANCER AND BENIGN OVARIAN TUMORS | TORAY INDUSTRIES, INC. (JP) | 2024-12-19 | — | — | US | disclosed |
| US-20240310266-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-09-19 | — | — | US | disclosed |
| US-11933753-B2 | Chemical sensing device | QI DIAGNOSTICS LTD (CN) | 2024-03-19 | — | — | US | disclosed |
| US-20230383282-A1 | TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-11-30 | — | — | US | disclosed |
| US-11781151-B2 | Insecticidal CRY1B variants having improved activity spectrum and uses thereof | PIONEER HI-BRED INTERNATIONAL, INC. | 2023-10-10 | — | — | US | disclosed |
| US-20230304065-A1 | METHODS FOR SCREENING COMPOUNDS FOR BACTERICIDAL ACTIVITY AND FOR DETERMINING THE SENSITIVITY OF BACTERIAL SAMPLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-09-28 | — | — | US | disclosed |
| US-4898856-A | Method for treating central nervous system diseases | AROONSAKUL CHAOVANEE (US) | 1990-02-06 | — | — | US | disclosed |
| US-4897389-A | Treating central nervous system diseases | AROONSAKUL CHAOVANEE (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0324037-A1 | Method of treatment of central nervous system diseases such as Alzheimer's disease and Parkinson's disease and method of diagnosing Alzheimer's disease | Aroonsakul, Chaovanee (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4791099-A | Method of treatment for central nervous system diseases such as Alzheimer's's disease | AROONSAKUL CHAOVANEE (US) | 1988-12-13 | — | — | US | disclosed |
| US-4778798-A | Pharmaceutical compositions having vasodilating and antianoxic activities | SEUREF A.G. (LI) | 1988-10-18 | — | — | US | disclosed |
| US-4778798-A | Pharmaceutical compositions having vasodilating and antianoxic activities | SEUREF A.G. (LI) | 1988-10-18 | — | — | US | disclosed |
| EP-0276543-A2 | Use of buspirone for the improvement of short term memory | Bristol-Myers Squibb Company (US) | 1988-08-03 | — | — | EP | disclosed |
| EP-0276536-A2 | Use of buspirone for the improvement of short term memory | Bristol-Myers Squibb Company (US) | 1988-08-03 | — | — | EP | disclosed |
| US-4687772-A | Method for improvement of short term memory | BRISTOL-MYERS COMPANY (US) | 1987-08-18 | — | — | US | disclosed |
| EP-0228036-A2 | Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom | Microgenesys, Inc. (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240310266-A1 | BIOMARKERS FOR CANCER AND METHODS OF USE THEREOF | PDCD1, PDCD1LG2, CD274 | LMNA 4013/4885NR1I2 4295/4885ABCB11 4686/4885 |
| US-12595504-B2 | Methods for screening compounds for bactericidal activity and for determining the sensitivity of bacterial samples | MRPL21, PGLS, CLPP | LMNA 1978/4885NR1I2 3197/4885ABCB11 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.